These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29306016)

  • 1. Pan-HDAC inhibition by panobinostat mediates chemosensitization to carboplatin in non-small cell lung cancer via attenuation of EGFR signaling.
    Wang L; Syn NL; Subhash VV; Any Y; Thuya WL; Cheow ESH; Kong L; Yu F; Peethala PC; Wong AL; Laljibhai HJ; Chinnathambi A; Ong PS; Ho PC; Sethi G; Yong WP; Goh BC
    Cancer Lett; 2018 Mar; 417():152-160. PubMed ID: 29306016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
    Garrett LA; Growdon WB; Rueda BR; Foster R
    J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer.
    Helland Ø; Popa M; Bischof K; Gjertsen BT; McCormack E; Bjørge L
    PLoS One; 2016; 11(6):e0158208. PubMed ID: 27352023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC.
    Piao J; Chen L; Quan T; Li L; Quan C; Piao Y; Jin T; Lin Z
    Oncotarget; 2016 Sep; 7(37):60169-60180. PubMed ID: 27507059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer.
    Tang YA; Wen WL; Chang JW; Wei TT; Tan YH; Salunke S; Chen CT; Chen CS; Wang YC
    PLoS One; 2010 Sep; 5(9):e12417. PubMed ID: 20856855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic priming of non-small cell lung cancer cell lines to the antiproliferative and differentiating effects of all-trans retinoic acid.
    Greve G; Schiffmann I; Lübbert M
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2171-80. PubMed ID: 26008188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells.
    Rao R; Balusu R; Fiskus W; Mudunuru U; Venkannagari S; Chauhan L; Smith JE; Hembruff SL; Ha K; Atadja P; Bhalla KN
    Mol Cancer Ther; 2012 Apr; 11(4):973-83. PubMed ID: 22367781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
    Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
    Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer.
    Ellis L; Ku SY; Ramakrishnan S; Lasorsa E; Azabdaftari G; Godoy A; Pili R
    Oncotarget; 2013 Dec; 4(12):2225-36. PubMed ID: 24163230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer.
    Geng L; Cuneo KC; Fu A; Tu T; Atadja PW; Hallahan DE
    Cancer Res; 2006 Dec; 66(23):11298-304. PubMed ID: 17145876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors.
    Kim JS; Lee SC; Min HY; Park KH; Hyun SY; Kwon SJ; Choi SP; Kim WY; Lee HJ; Lee HY
    Cancer Lett; 2015 Jun; 361(2):197-206. PubMed ID: 25721083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells.
    Greve G; Schiffmann I; Pfeifer D; Pantic M; Schüler J; Lübbert M
    BMC Cancer; 2015 Dec; 15():947. PubMed ID: 26675484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel histone deacetylase inhibitors derived from Magnolia officinalis significantly enhance TRAIL-induced apoptosis in non-small cell lung cancer.
    Liu Y; Tong Y; Yang X; Li F; Zheng L; Liu W; Wu J; Ou R; Zhang G; Hu M; Liu Z; Lu L
    Pharmacol Res; 2016 Sep; 111():113-125. PubMed ID: 27268146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors.
    Gray JE; Haura E; Chiappori A; Tanvetyanon T; Williams CC; Pinder-Schenck M; Kish JA; Kreahling J; Lush R; Neuger A; Tetteh L; Akar A; Zhao X; Schell MJ; Bepler G; Altiok S
    Clin Cancer Res; 2014 Mar; 20(6):1644-55. PubMed ID: 24429877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Li F; Zhu T; Cao B; Wang J; Liang L
    Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization.
    Fischer C; Leithner K; Wohlkoenig C; Quehenberger F; Bertsch A; Olschewski A; Olschewski H; Hrzenjak A
    Mol Cancer; 2015 Jan; 14():4. PubMed ID: 25608569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro.
    Chao H; Wang L; Hao J; Ni J; Chang L; Graham PH; Kearsley JH; Li Y
    Cancer Lett; 2013 Feb; 329(1):17-26. PubMed ID: 22995071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Panobinostat sensitizes KRAS-mutant non-small-cell lung cancer to gefitinib by targeting TAZ.
    Lee WY; Chen PC; Wu WS; Wu HC; Lan CH; Huang YH; Cheng CH; Chen KC; Lin CW
    Int J Cancer; 2017 Nov; 141(9):1921-1931. PubMed ID: 28710768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
    Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
    PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pan-deacetylase inhibitor panobinostat affects angiogenesis in hepatocellular carcinoma models via modulation of CTGF expression.
    Gahr S; Mayr C; Kiesslich T; Illig R; Neureiter D; Alinger B; Ganslmayer M; Wissniowski T; Fazio PD; Montalbano R; Ficker JH; Ocker M; Quint K
    Int J Oncol; 2015 Sep; 47(3):963-70. PubMed ID: 26202945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.